Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT03055234 Withdrawn - Clinical trials for Pulmonary Hypertension Associated With Sickle Cell Disease

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Start date: June 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell disease (SCD). Once enrolled, subjects will be evaluated at Weeks 6, 12, 24, and then every 12 weeks for the duration of the study. Subjects will be permitted to enter a 48-week open-label extension period if they experience a PH clinical worsening event.

NCT ID: NCT03016468 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Start date: May 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH). The study will include about 30 subjects at approximately 10 clinical trial centers. The treatment phase of the study will last approximately 16 weeks.

NCT ID: NCT03012646 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).

NCT ID: NCT02999906 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Start date: October 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan, tadalafil) for at least 30 days at randomization for their PAH. Once randomized, subjects will return for 5 study visits up to Week 28 during the blinded period. After the Week 28 Visit, eligible subjects will transition to the open-label period of the study for up to 20 weeks.

NCT ID: NCT02969265 Withdrawn - Hypertension Clinical Trials

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Start date: May 9, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach target blood pressure following 4 weeks of treatment with amlodipine monotherapy.

NCT ID: NCT02958358 Withdrawn - Clinical trials for Pulmonary Arterial Hypertension

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

Start date: September 2014
Phase: N/A
Study type: Interventional

The investigators are doing this research study to find out how blood flow changes in the lungs of people with pulmonary hypertension before and after treatment with ambrisentan (sold under the brand name Letairis). The investigators hope that knowing about these differences will help us to better understand pulmonary hypertension and find new ways to diagnose it earlier.

NCT ID: NCT02955368 Withdrawn - Hypertension Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

Start date: February 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

NCT ID: NCT02933593 Withdrawn - Hypertension Clinical Trials

Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

Start date: August 2016
Phase: N/A
Study type: Interventional

The investigators plan to monitor the central blood pressure in women with severely elevated blood pressures (160/110) in pregnancy in the acute setting. Currently ACOG recommends 3 different options for blood pressure control, however no one has studied how these medications affect the central pressures, only peripheral blood pressure.

NCT ID: NCT02926495 Withdrawn - Clinical trials for Resistant Hypertension

Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.

Start date: November 2016
Phase: N/A
Study type: Interventional

Hypertension is a serious public health issue, affecting approximately 30% of adults. Hypertension greatly contributes to the risk for heart disease and stroke, both among the top three leading causes of death in the Americas, Europe, and Asia. While most treated individuals with hypertension are controlled on medication, diet and exercise, an estimated 12% are resistant to conventional medical intervention. Alternative effective treatments are still needed for this hypertensive patient population to mitigate the risk and incidence of mortality and morbidity. This original Investigational Device Application is for a study intended to confirm the safety and efficacy of bilateral subcutaneous median nerve stimulation using the eCoin system to treat resistant hypertension. The eCoin device delivers electrical stimulation pulses to the median nerve from a small coin sized device placed under the skin of the distal anterior forearm. The implant delivers a weekly 30 minute treatment based on previous studies showing a long lasting and cumulative effect. The safety and efficacy of eCoin therapy has previously been demonstrated in a multinational, randomized, double-blind, sham-controlled study in New Zealand, Taiwan and Canada. This trial is a multi-center, prospective, double-blind, 1:1 randomized sham-controlled study of the safety and effectiveness of eCoin median nerve neuromodulation in subjects with drug-treatment resistant hypertension. The eCoin neuromodulation device will be implanted subcutaneously in the right and left forearms of patients with uncontrolled hypertension despite treatment with 3 or more antihypertensive agents. After a 4 week implant healing period, subjects will be 1:1 randomized into either a treatment or control group. One half of the subjects have their devices activated (treatment) and the other half undergo a sham activation (control) to maintain participant blinding to their treatment allocation. During the six months post-randomization, the eCoin is ON in the treatment group and OFF in the control group.

NCT ID: NCT02912910 Withdrawn - Hypertension Clinical Trials

Changes in Central Arterial Pressure When Comparing Nifedipine/Labetalol for Routine Hypertension Control in Pregnancy

Start date: September 2016
Phase: N/A
Study type: Observational

To study central blood pressure changes caused by commonly used high blood pressure medications in pregnancy.